169 related articles for article (PubMed ID: 36526013)
1. Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy.
Prakash A; Gates T; Zhao X; Wangmo D; Subramanian S
Pharmacol Ther; 2023 Jan; 241():108332. PubMed ID: 36526013
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic tumor cell-derived extracellular vesicles stimulate CD8 T cell response in colorectal cancer.
Gates TJ; Wangmo D; Zhao X; Subramanian S
Mol Ther Oncolytics; 2023 Dec; 31():100727. PubMed ID: 37822487
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic Tumor Cell-Derived Extracellular Vesicles Stimulate CD8 T Cell Response in Colorectal Cancer.
Gates TJ; Wangmo D; Zhao X; Subramanian S
bioRxiv; 2023 Apr; ():. PubMed ID: 37131597
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Derived Extracellular Vesicles and the Immune System-Lessons From Immune-Competent Mouse-Tumor Models.
Droste M; Thakur BK; Eliceiri BP
Front Immunol; 2020; 11():606859. PubMed ID: 33391275
[TBL] [Abstract][Full Text] [Related]
5. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses.
Zhao X; Yuan C; Wangmo D; Subramanian S
Gastroenterology; 2021 Aug; 161(2):560-574.e11. PubMed ID: 33895168
[TBL] [Abstract][Full Text] [Related]
7. The capture of extracellular vesicles endogenously released by xenotransplanted tumours induces an inflammatory reaction in the premetastatic niche.
Blavier L; Nakata R; Neviani P; Sharma K; Shimada H; Benedicto A; Matei I; Lyden D; DeClerck YA
J Extracell Vesicles; 2023 May; 12(5):e12326. PubMed ID: 37194998
[TBL] [Abstract][Full Text] [Related]
8. The immunomodulatory role of tumor-derived extracellular vesicles in colorectal cancer.
Manning S; Danielson KM
Immunol Cell Biol; 2018 Mar; ():. PubMed ID: 29575270
[TBL] [Abstract][Full Text] [Related]
9. Insight into immune checkpoint inhibitor therapy for colorectal cancer from the perspective of circadian clocks.
Liu Y; Wang Z; Hao H; Wang Y; Hua L
Immunology; 2023 Sep; 170(1):13-27. PubMed ID: 37114514
[TBL] [Abstract][Full Text] [Related]
10. Tumor-derived extracellular vesicles in breast cancer: From bench to bedside.
Wang HX; Gires O
Cancer Lett; 2019 Sep; 460():54-64. PubMed ID: 31233837
[TBL] [Abstract][Full Text] [Related]
11. Circulating extracellular vesicles derived from tumor endothelial cells hijack the local and systemic anti-tumor immune response: Role of mTOR/G-CSF pathway.
Koni M; Lopatina T; Grange C; Sarcinella A; Cedrino M; Bruno S; Buffolo F; Femminò S; Camussi G; Brizzi MF
Pharmacol Res; 2023 Sep; 195():106871. PubMed ID: 37506784
[TBL] [Abstract][Full Text] [Related]
12. Molecular Determinants Involved in the Docking and Uptake of Tumor-Derived Extracellular Vesicles: Implications in Cancer.
Clares-Pedrero I; Rocha-Mulero A; Palma-Cobo M; Cardeñes B; Yáñez-Mó M; Cabañas C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542421
[TBL] [Abstract][Full Text] [Related]
13. Development of CD40L-modified tumor small extracellular vesicles for effective induction of antitumor immune response.
Liu W; Takahashi Y; Morishita M; Nishikawa M; Takakura Y
Nanomedicine (Lond); 2020 Jul; 15(17):1641-1652. PubMed ID: 32664826
[No Abstract] [Full Text] [Related]
14. Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1.
Chen J; Yang J; Wang W; Guo D; Zhang C; Wang S; Lu X; Huang X; Wang P; Zhang G; Zhang J; Wang J; Cai Z
Cell Mol Immunol; 2022 Nov; 19(11):1290-1301. PubMed ID: 36220994
[TBL] [Abstract][Full Text] [Related]
15. CD44 and Tumor-Derived Extracellular Vesicles (TEVs). Possible Gateway to Cancer Metastasis.
Szatanek R; Baj-Krzyworzeka M
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540535
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
17. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
18. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.
Chen L; Jiang X; Li Y; Zhang Q; Li Q; Zhang X; Zhang M; Yu Q; Gao D
Clin Immunol; 2022 Apr; 237():108962. PubMed ID: 35227870
[TBL] [Abstract][Full Text] [Related]
19. Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology.
Liu Z; Xiang Y; Zheng Y; Kang X
Front Immunol; 2022; 13():1027124. PubMed ID: 36341334
[TBL] [Abstract][Full Text] [Related]
20. Novel Personalized Cancer Vaccine Using Tumor Extracellular Vesicles with Attenuated Tumorigenicity and Enhanced Immunogenicity.
Han J; Kim S; Hwang YH; Kim SA; Lee Y; Kim J; Cho S; Woo J; Jeong C; Kwon M; Nam GH; Kim IS
Adv Sci (Weinh); 2024 Apr; ():e2308662. PubMed ID: 38666427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
